A clinical study on the effects of recombinant human colony stimulating factor on the expression of Bcl-2 in serum of patients with basal ganglia hemorrhage and its clinical significance

OBJECTIVE: We investigated the effects of the colony-stimulating factor (CSF-1) on Bcl-2 expression in serums of patients with basal ganglia hemorrhage and subsequently, its clinical significance.

PATIENTS AND METHODS: The expression levels of Bcl-2 in serums of patients with basal ganglia hemorrhage were analyzed, and the effects of the CSF-1 on Bcl-2 expression were observed. Samples of peripheral blood were taken from 120 patients with basal ganglia hemorrhage admitted to the Neurology Department and 120 healthy people undergoing a physical examination at Xiangyang Central Hospital between May 2013 to December 2014. The detection of Bcl-2 levels in serums of patients was performed using the ELISA method, and patients were divided into two groups, the colony-stimulating factor (CSF-1) group and the control group. The CSF-1 group was treated with recombinant human granulocyte colony-stimulating factor after routine treatment, while the control group was treated only with routine treatment. The two groups of patients were followed up for observation of treatment effects.

RESULTS: Before treatment, serum Bcl-2 levels in both the CSF-1 and control group showed no significant differences; however, their levels were significantly higher than those of the healthy cohort (p<0.05). After treatment, serum Bcl-2 levels of the CSF-1 group were significantly higher than those of the control group (p<0.05). However, compared to the healthy control group, the levels remained significantly higher and the differences were statistically significant (p<0.05). When compared to the recovering conditions of patients in the CSF-1 group and the control group, we found that the average hospitalization time and occurrences of complications in the CSF-1 group were significantly less than those in the control group (p<0.05).

CONCLUSIONS: CSF-1 is clinically effective in improving the serum Bcl-2 levels after a basal ganglia hemorrhage, and it can be used as adjuvant therapy in the treatment of basal ganglia hemorrhage.

L'articolo A clinical study on the effects of recombinant human colony stimulating factor on the expression of Bcl-2 in serum of patients with basal ganglia hemorrhage and its clinical significance sembra essere il primo su European Review.

http://ift.tt/2tuI72U